LDS/Medical Tests/Breast and Ovarian Hereditary Cancer Panel, Sequencing and Deletion/Duplication (OvaNext®)

Breast and Ovarian Hereditary Cancer Panel, Sequencing and Deletion/Duplication (OvaNext®)

Hereditary breast and ovarian cancer (HBOC) syndrome is an autosomal dominant disease primarily associated with mutations in BRCA1 or BRCA2 genes. In addition to BRCA1 and BRCA2, there are some other gene mutation associated with HBOC that may also be used in the evaluation of risk for breast and ovarian cancer. Other less common genes include: TP53, PTEN, CDH1, ATM, CHEK2 or PALB2 and STK11. The main characteristics of the HBOC is increased risk of breast and ovarian cancers. In addition, patients with these mutations have increased risk of other cancers such as pancreatic cancer, fallopian tube cancer, male breast cancer, prostate cancer, and melanoma. Current data indicate the risk of developing breast cancer is around 5-10% and 10-15% for ovarian cancers in patients harboring such mutations.

Genetic testing for BRCA1 and BRCA2 will identify 88-90% of HBOC cases. Expanded multi-gene panel that includes most common gene mutations with HBOC including TP53, PTEN, CDH1, ATM, CHEK2 or PALB2 and STK11 will detect additional cases and may be useful in BRCA1/2 negative patients when there is a suspicion of hereditary cancer susceptibility.

  • Screening for hereditary breast and ovarian cancer syndrome
  • Screening for hereditary susceptibility to breast and ovarian cancer and cancer risk-reducing management
  • As an aid in diagnosis and prognosis of breast and ovarian cancer
  • Potential information for preventive and pre-emptive therapy or intervention
Positive results will report detected variation (pathogenic variation). Mutation in any of these genes will indicate increase risk in breast and ovarian cancer and will confirm diagnosis of Hereditary Breast and Ovarian cancer.

Negative for mutation analyzed (No reportable variants were identified)

Next generation Sequencing (NGS) with Deletion/Duplication Analysis.

Whole blood (EDTA). 

Stability

  • Ambient: 5-7 days
  • Refrigerated: 7-14 days
Breast and or ovarian biopsy (Fine needle aspiration), Hormone Receptor Status, Her2neu by IHC and FISH, ER/PR by IHC, Cancer Antigen 15-3 (CA 15-3, CEA.
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login